Phase II Trial of Nivolumab and HPV-16 Vaccination in Patients With HPV-16-Positive Incurable Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs ISA 101 (Primary) ; Nivolumab
- Indications Solid tumours
- Focus Therapeutic Use
- 15 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Dec 2015 Planned primary completion date changed from 1 Feb 2019 to 1 Dec 2018, as reported by ClinicalTrials.gov.
- 07 Dec 2015 Status changed from not yet recruiting to recruiting, as reported in an ISA Pharmaceuticals media release.